Institutional investors purchased a net $737.1 thousand shares of RGEN during the quarter ended December 2012. This may signal that the smart money is gaining interest in this company as the 54.83% of shares outstanding that institutional investors hold is actually below the Biotechnology industry average.
Mutual fund holders
Largest Quarterly Institutional Transactions
Latest Institutional Activity
NORTHPOINTE CAPITAL LLC Bought 795.7 Thousand shares of Repligen Corp
CADENCE CAPITAL MANAGEMENT LLC Bought 168.9 Thousand shares of Repligen Corp
PYRAMIS GLOBAL ADVISORS LLC Bought 107.6 Thousand shares of Repligen Corp